Eric Schmidt (biotech analyst)
Biotech analyst
“early this year the Stock was at 80 and there was rumor that Merck was going to buy them for maybe a whopping 50% premium around 120... there was no deal. And today what the stock's hitting new highs at 180.”
“This is definitively... a better mousetrap than Exhaud in terms of everything... given the very, very, very low benchmark that was set by the FDA and by Sarepta years ago, it's pretty hard to see how this doesn't get approved.”
Eric Schmidt (biotech analyst)
One-line summary: Biotech Hangout panelist. NOTE: not the former Google CEO — disambiguated slug.
What they're known for
Brief factual context — fill in.
Why they matter to stock-market
Why this person's claims are tracked here — fill in.
Said
Speaker-attributed claims extracted from diarized sources. Each bullet mirrors one entry in quotes: frontmatter — keep them in sync.
-
On (no topic linked):
"early this year the Stock was at 80 and there was rumor that Merck was going to buy them for maybe a whopping 50% premium around 120... there was no deal. And today what the stock's hitting new highs at 180." — 2026-06-26-podcast-biotech-hangout-episode-187-june-26-2026 (2026-06-26)
-
On fda-right-shift-to-rare-disease-refile-rerate:
"This is definitively... a better mousetrap than Exhaud in terms of everything... given the very, very, very low benchmark that was set by the FDA and by Sarepta years ago, it's pretty hard to see how this doesn't get approved." — 2026-07-24-podcast-biotech-hangout-episode-190-july-24-2026 (2026-07-24)
Sources
- 2026-06-26-podcast-biotech-hangout-episode-187-june-26-2026
- 2026-07-24-podcast-biotech-hangout-episode-190-july-24-2026
Related
Cross-links — fill in.